In a patient with metastatic clear cell RCC who achieved a prolonged PR with first line nivolumab/ipilimumab, discontinued due to IRAEs, would you consider a TKI/checkpoint inhibitor combination regimen?   

The question of the utility of IO after IO in mRCC is an important one that has not yet been adequately studied. As of now, I believe single agent VEGF TKI is standard of care in this setting (or perhaps lenvatinib/everolimus). There are some retrospective data about Ipi/nivo after prior IO with som...